In recent years, clinical research shows the trend of globalization. Due to characteristics of the huge number and relative concentration of patients, the wide variety of diseases, a high patient enrolment rate, lower trials costs, and so on, China and India become a focus of this trend. However, China and India also have their own advantages in the aspects of diseases, infrastructure, policies, regulations, regulatory environment, language, and culture. The key question to address is: how to increase the shares in the trial market in the future and to enhance the international status of China’s clinical research? Before we answer this question, we must understand the present situations of clinical research resources in China and India. So, we searched the relevant literature at home and abroad by computer and hand to analyze advantages and efficiency of clinical research resources in China and India.
The widespread application of composite endpoints in clinical research has afforded researchers a more comprehensive perspective, enabling a deeper understanding of intricate medical issues. Simultaneously, it effectively enhances the efficiency and efficacy of studies, thereby reducing the overall economic costs of research. A profound comprehension of the strengths and limitations of composite endpoints is crucial for their correct application and the accurate interpretation of results. This paper aims to introduce the recent advancements in the application of composite endpoints in clinical trials, discussing their advantages and limitations, and providing practical recommendations for their use. The intention is to offer guidance to researchers in understanding and managing composite endpoints effectively.